Tag: business operations

MARKHAM, Ontario, June 26, 2025 (GLOBE NEWSWIRE) -- Extendicare Inc. (“Extendicare” or the “Company”) (TSX: EXE) announced today that the Toronto Stock Exchange (the “TSX”) has approved the renewal of Extendicare’s normal course issuer bid (“NCIB”). Under the terms of the NCIB, the Company may purchase for cancellation up to 7,281,193 of its common shares (the “Common Shares”), representing 10% of its public float of issued and outstanding Common Shares. As at June 20, 2025, there were 83,817,909 Common Shares issued and outstanding and the public float was 72,811,939 Common Shares, calculated in accordance with the rules of the TSX.

SHANGHAI, June 26, 2025 (GLOBE NEWSWIRE) -- Everest Medicines (HKEX 1952.HK, “Everest”, or the “Company”), a biopharmaceutical company focused on the discovery, clinical development, manufacturing, and commercialization of innovative therapeutics, today announced that it will host a virtual nephrology-focused key opinion leader (KOL) event on Monday, June 30, 2025 at 8:00 AM ET. For English speakers, please click here to register. For individuals preferring instant Chinese translation, please click here.

Basel, June 25, 2025 – Novartis today announced that it has successfully completed its acquisition of Regulus Therapeutics Inc. (“Regulus”). With the completion of the acquisition, shares of common stock, par value $0.001 per share (the “Shares”), of Regulus, have ceased trading on the Nasdaq Stock Market LLC and Regulus is now an indirect wholly owned subsidiary of Novartis.

CUE-401, a first-in-class bispecific molecule designed to induce and expand Tregs in vivo through the co-activity of transforming TGF-β and a modified variant of IL-2